Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 88Myeloid 57Lymphoid 57Plasma cell 28Classical hematology 15Dermatologic 13Sarcoma 7Other neoplasm 4Genitourinary 4Gynecologic 3CNS 3Breast 2Thoracic 1Other 1

Conditions

Mucositis 44Obesity 23Neoplasms 19Head and Neck Neoplasms 15Stomatitis 12Dyspnea 12Constipation 10Sexual Dysfunction, Physiological 8Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 7Overweight 6Xerostomia 5Prostatic Neoplasms 5Radiation Injuries 4Opioid-Induced Constipation 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycystic Ovary Syndrome 3Pain 3Nausea 3Mouth Neoplasms 3Hematologic Neoplasms 3Colorectal Neoplasms 3Tongue Neoplasms 2Salivary Gland Neoplasms 2Multiple Myeloma 2Mouth Diseases 2Leukemia 2Intestinal Diseases 2Infertility 2Febrile Neutropenia 2

Interventions

angiotensin I (1-7) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Graft vs Host Disease × Other × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡